ATG-031 

ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

CD24

ATG-031 potently binds to CD24-postive tumor cells, while showing no binding with parental HEK293 cells or hRBC^[1].
ATG-031 blocks the interaction between CD24 and Siglec-10 and induces potent macrophage-dependent tumor cell phagocytosis^[1].
ATG-031 induces a potent antibody-dependent cellular cytotoxicity against HT-29 tumor cells with an EC₅₀ of 0.27 nM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ATG-031 (1-3 mg/kg, i.v., biweekly) significantly inhibits tumor growth and induces tumor regression in MC38-hCD24 mouse model^[1].
ATG-031 exhibits potent antitumor activity in vivo as a single agent in syngeneic models such as MC38, CT26, and 4T1^[3].
ATG-031 demonstrates in vivo synergism with chemotherapies and checkpoint inhibitors^[3].
ATG-031 (3 mg/kg, i.v., 2 doses) significantly increases T cell-associated immune response at the cellular and single-cell transcriptome levels in C57BL/6 mice bearing MC38-hCD24 tumors^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

100134000  [NCBI]

P25063-1

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.305 kDa

Liquid

Colorless to light yellow

[ATG-031]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Loaded CD24 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78913) on AHC2 biosensor, can bind ATG-031 with an affinity constant of 8.121E-09 M as determined in BLI assay.
• 
  Flow cytometric analysis of 1×10⁶ MCF-7 cells labelling CD24 (red) with ATG-031 (HY-P99176). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa Isotype Control (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Immobilized Biotinylated Human CD24, at 5 μg/mL (100 μL/well, HY-P78913) on streptavidin precoated (0.5 μg/well) plate, can bind Anti-CD24 Mab (HY-P99176). The ED50 for this effect is 2.899 ng/mL.

• [1]. Peng Chen, et al., (2022). ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking “don’t-eat-me” signal. Journal for ImmunoTherapy of Cancer 2022.

  [2]. Peng Chen, et al., Abstract 6641: ATG-031, a first-in-class humanized anti-CD24 antibody, demonstrates potent in vivo efficacy and repolarizes tumor-associated macrophages in the TME. Cancer Res 1 April 2023; 83 (7_Supplement): 6641.

  [3]. Chen P, et al., 1337 The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignanciesJournal for ImmunoTherapy of Cancer 2023;11